Alpha-blockers and converting enzyme inhibitors.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007217:Indoramin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D007700:Kinetics; D007741:Labetalol / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D011224:Prazosin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007217:Indoramin; D002216:Captopril; D007741:Labetalol; D011224:Prazosin